Equities

Aurisco Pharmaceutical Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Aurisco Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)26.95
  • Today's Change-0.08 / -0.30%
  • Shares traded3.11m
  • 1 Year change+33.61%
  • Beta0.3209
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Aurisco Pharmaceutical Co Ltd is a China-based company mainly engaged in the research and development, production and sales of specialty APIs and pharmaceutical intermediates. The Company's APIs and intermediates are mainly respiratory, cardiovascular, anti-infection, nervous system, anti-tumor and women's health products, including flumethasone, fluticasone propionate, eplerenone, tenofovir, pregabalin and other APIs and intermediates. The Company sells products in the domestic market and overseas markets.

  • Revenue in CNY (TTM)1.62bn
  • Net income in CNY424.54m
  • Incorporated1998
  • Employees1.78k
  • Location
    Aurisco Pharmaceutical Co LtdNo. 1 Longxing RoadBadu Industrial Park, Tiantai CountyTAIZHOU 317200ChinaCHN
  • Phone+86 57 683170900
  • Fax+86 57 683170900
  • Websitehttps://www.aurisco.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Youcare Pharmaceutical Group Co Ltd2.55bn-233.99m10.24bn3.28k--2.99--4.02-0.5306-0.53065.757.620.45372.184.03777,123.10-4.305.90-5.978.9247.5563.64-9.487.491.49-41.240.163366.99-9.90-2.48-33.05-15.4019.36--
Chongqing Genrix Biophrmctcl Co Ltd225.16m-583.52m10.63bn743.00--5.94--47.19-1.59-1.590.61414.880.07120.308810.33303,044.90-18.45---19.95--90.99---259.16--7.37--0.3694--2,384.11--0.5049------
Liaoning Chengda Biotechnology Co Ltd1.47bn177.94m10.79bn1.81k59.811.15--7.340.4330.4333.5622.540.14820.67861.24813,192.101.798.071.868.3679.0384.9812.1135.7519.28--0.001344.77-4.22-0.0082-26.42-13.26-4.72--
Jiangsu Sinopep Allsin Bphrmctcl Co Ltd1.90bn498.69m10.94bn2.03k21.713.52--5.761.601.606.139.840.34130.93063.06936,748.908.907.1913.049.6766.6459.3026.0820.280.92816.070.460435.8957.2134.33148.1952.7631.58--
Aurisco Pharmaceutical Co Ltd1.62bn424.54m10.98bn1.78k25.564.32--6.761.061.064.076.260.41881.094.41910,578.1010.9411.3712.6013.2959.7752.9326.1322.343.01635.150.280631.5316.8920.4722.5913.7749.45--
Shanghai Yizhong Pharmaceutical Co Ltd247.05m22.96m11.30bn65.00483.127.74--45.750.11320.11321.227.070.1630.95562.263,800,801.001.515.441.585.6481.3992.999.3036.907.84--0.0032.30-51.83---95.68--10.96--
Zhejiang CONBA Pharmaceutical Co., Ltd.6.58bn687.99m11.46bn8.26k16.961.62--1.740.26650.26652.542.800.66172.574.70796,529.007.138.519.6512.7451.8858.6410.7714.121.38--0.053241.54-3.23-0.75945.21--1.57--
Cansino Biologics Inc971.83m-142.03m11.61bn1.11k--3.06--11.95-0.5455-0.54553.9221.370.12710.58611.38879,482.50-1.86-4.08-2.29-5.3878.8045.31-14.62-27.513.29--0.2242--137.01226.4374.45--31.38--
Mayinglong Pharmaceutical Group Co Ltd3.77bn571.60m11.87bn2.65k20.772.76--3.151.331.338.759.970.72116.2311.991,421,812.0011.3810.7713.8213.3546.7742.4015.7814.394.58--0.022637.3118.856.6219.147.9734.4718.98
Jiangxi Tianxin Pharmaceutical Co Ltd2.23bn617.04m12.01bn2.68k19.382.51--5.401.421.425.1110.930.39732.439.65830,883.1011.0117.1011.8821.1643.0442.9927.7230.124.31--0.072124.4117.351.7536.85-2.2035.06--
Data as of Feb 11 2026. Currency figures normalised to Aurisco Pharmaceutical Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

1.19%Per cent of shares held by top holders
HolderShares% Held
China Southern Asset Management Co., Ltd.as of 30 Jun 20251.13m0.29%
Fullgoal Fund Management Co., Ltd.as of 30 Jun 20251.02m0.26%
China Asset Management Co., Ltd.as of 30 Jun 2025853.80k0.22%
GF Fund Management Co., Ltd.as of 30 Jun 2025536.50k0.14%
Fuanda Fund Management Co., Ltd.as of 30 Jun 2025286.20k0.07%
Dimensional Fund Advisors LPas of 08 Jan 2026267.00k0.07%
China Life AMP Asset Management Co., Ltd.as of 30 Jun 2025210.00k0.05%
VanEck Australia Pty Ltd.as of 08 Jan 2026146.10k0.04%
GF Securities Asset Management (Guangdong) Co., Ltd.as of 30 Jun 2025130.00k0.03%
CCB Principal Asset Management Co., Ltd.as of 30 Jun 2025103.60k0.03%
More ▼
Data from 30 Jun 2025 - 05 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.